- Home
- CANG vs HQL Comparison
CANG vs HQL Comparison
Compare CANG & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANG
- HQL
- Stock Information
- Founded
- CANG 2010
- HQL 1992
- Country
- CANG China
- HQL United States
- Employees
- CANG N/A
- HQL N/A
- Industry
- CANG Computer Software: Prepackaged Software
- HQL Investment Managers
- Sector
- CANG Technology
- HQL Finance
- Exchange
- CANG Nasdaq
- HQL Nasdaq
- Market Cap
- CANG 392.4M
- HQL 391.1M
- IPO Year
- CANG 2018
- HQL N/A
- Fundamental
- Price
- CANG $3.98
- HQL $13.82
- Analyst Decision
- CANG
- HQL
- Analyst Count
- CANG 0
- HQL 0
- Target Price
- CANG N/A
- HQL N/A
- AVG Volume (30 Days)
- CANG 427.7K
- HQL 120.9K
- Earning Date
- CANG 11-04-2024
- HQL 01-01-0001
- Dividend Yield
- CANG N/A
- HQL 11.56%
- EPS Growth
- CANG N/A
- HQL N/A
- EPS
- CANG 0.19
- HQL 0.79
- Revenue
- CANG $38,020,222.00
- HQL N/A
- Revenue This Year
- CANG $253.48
- HQL N/A
- Revenue Next Year
- CANG N/A
- HQL N/A
- P/E Ratio
- CANG $18.83
- HQL $17.08
- Revenue Growth
- CANG N/A
- HQL N/A
- 52 Week Low
- CANG $0.92
- HQL $11.34
- 52 Week High
- CANG $4.20
- HQL $14.37
- Technical
- Relative Strength Index (RSI)
- CANG 72.51
- HQL 33.30
- Support Level
- CANG $3.40
- HQL $13.70
- Resistance Level
- CANG $4.20
- HQL $14.37
- Average True Range (ATR)
- CANG 0.38
- HQL 0.27
- MACD
- CANG 0.05
- HQL -0.10
- Stochastic Oscillator
- CANG 98.19
- HQL 6.51
About CANG Cango Inc. each representing two (2)
Cango Inc is an automotive transaction service platform in China connecting dealers, financial institutions, car buyers, and other industry participants. The services mainly consist of - automotive financing facilitation, automotive transaction facilitation, and aftermarket service facilitation. Geographically, it derives revenue from China.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.